Pietro De Placido, Medical Oncologist at Dana-Farber Cancer Institute, a post on X about a paper by Kerstin Pfister et al. published in Journal of Clinical Oncology:
“The SURVIVE Study (NCT05658172) will challenge the ‘no symptoms, no scan’ BC surveillance model.
3,500 high-risk EBC patients will be randomized to standard vs. liquid biopsy-guided follow-up.
Costly if effective? Prevention beats cure.”
Authors: Kerstin Pfister, Sophia Huesmann, Thomas Friedl, Brigitte Rack, Wolfgang Janni et al.
More posts featuring Pietro De Placido.